METUCHEN, N.J.--(BUSINESS WIRE)--Tevogen Bio announces the appointment of its Chairman and CEO Ryan Saadi, M.D., M.P.H. to the Yale School of Public Health (YSPH) Leadership Council. Dr. Saadi joins an esteemed and diverse Council comprised of Yale alumni and preeminent national leaders who share a unified commitment to improving public health on a local and global scale and ending the prevailing issue of health inequity.
“Dr. Saadi is a crusader in the fight against health inequity. Throughout his distinguished career, he has demonstrated an unwavering dedication to the improvement of the health of all people,” said Sten H. Vermund, M.D., Ph.D., Dean of the Yale School of Public Health and the Anna M.R. Lauder Professor of Public Health. “We are proud to welcome him to our Council where his expertise, innovative spirit and dedication to our mission will prove invaluable.”
The Leadership Council is committed to advancing YSPH as a global leader in public health. Among its goals is to close the gap of healthcare inequity in communities across the U.S. and the world.
“Dr. Saadi brings with him a unique expertise at the intersection of public health and technological innovation in the healthcare space,” said Council Vice-Chair Clarion E. Johnson, M.D., who retired from ExxonMobil as its Global Medical Director and presently serves as Co-Chair of the Public Private Partnership at the National Academy of Sciences. “His passion for solving long-standing problems, including public health disparities among those of lower socioeconomic groups, is apparent in his founding of Tevogen Bio, which strives to be the first public health-centric biotechnology company.”
“I’m honored and humbled to join this esteemed group of pioneers in the public health space who, individually and collectively, are committed to the vital work of improving the health of all people,” said Dr. Saadi, who obtained his M.P.H. in Infectious Diseases from Yale University in 1995. “We must ensure access to medical innovations to all, and I personally believe that novel patient centric biopharma business model is necessary to sustain medical innovation in the post pandemic world. My goal in creating Tevogen Bio deeply aligns with the vision of Dean Vermund which is to not only reinforce our public health structure, but to address health care inequity by ensuring affordable lifesaving therapies are available to all people regardless of socioeconomic status.”
Tevogen’s investigational T cell immunotherapy for high-risk patients with COVID-19, TVGN-489, is currently in clinical trials at Thomas Jefferson University in Philadelphia. TVGN-489 is highly purified SARS-CoV-2 specific cytotoxic CD8+ T lymphocytes (CTLs) programmed to detect multiple targets spread across the entire viral genome. These targeted CTLs are expected to transfer immunity to SARS-CoV-2 by recognizing and killing off viral infected cells, ridding the body of infection. TVGN-489 has demonstrated strong antiviral activity against SARS-CoV-2 in preclinical studies.
About Tevogen Bio
Tevogen Bio is driven by a team of distinguished scientists and highly experienced biopharmaceutical leaders who have successfully developed and commercialized multiple franchises. In collaboration with key strategic partners, the company moved its lead product from discovery to clinical phase within 12 months of inception, shaving years off the industry’s standard for drug development timelines.
Tevogen leadership believes that affordable personalized immunotherapies are the next frontier of medicine and disruptive business models are required to sustain medical innovation in the post pandemic world. The company’s breakthrough technology overcomes traditional barriers to the broad application of targeted T cell therapies through revolutionary advances in speed to patient and product purity. Tevogen’s focus on organizational and manufacturing efficiency is core to its highly successful biopharma business model and goal to make personalized immunotherapies accessible to the masses for the first time. Tevogen Bio’s research pipeline includes targeted CD8+ T Lymphocyte therapeutics for the treatment of common cancers (NSCLC, Cervical Cancer) and difficult to eradicate serious viral infections (Hepatitis B).
About Yale School of Public Health
Established in 1915 as one of the first schools of public health in the United States, the Yale School of Public Health (YSPH) is consistently ranked among the best schools of public health in the country. A CEPH-certified school of public health, YSPH is at the forefront of advancing education, science and public health for the 21st century. The school has a long history of leading responses to emerging infectious diseases: contributing to the development of a polio vaccine in the 1960s, addressing arboviruses like dengue in the 1980s, HIV/AIDS in the 1990s, the epidemics of Ebola, Zika and most recently COVID-19. With a focus on health equity and anti-racism, YSPH seeks to mitigate harms from climate change, pandemic threats, chronic diseases, and inaccessibility to healthcare.
Forward Looking Statements
This press release contains certain forward-looking statements relating to Tevogen Bio™ Inc.’s (the “Company”) development and patient access of its innovations in infectious diseases and oncology. These statements are based on management’s current expectations and beliefs as of the date of this release and are subject to a number of factors which involve known and unknown risks, delays, uncertainties and other factors not under the company’s control which may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations implied by these forward-looking statements. In any forward-looking statement in which the Company expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. These factors include results of current or pending clinical trials, risks associated with intellectual property protection, financial projections, sales, pricing and actions by the FDA/EMA. The Company undertakes no obligation to update the forward-looking statements or any of the information in this release, or provide additional information, and expressly disclaims any and all liability and make no representations or warranties in connection herewith or with respect to any omissions herefrom.
